医学
荟萃分析
萧条(经济学)
难治性抑郁症
氯胺酮
内科学
重性抑郁障碍
精神科
认知
经济
宏观经济学
作者
Stevan Nikolin,Anthony Rodgers,Andreas Schwaab,Anees Bahji,Carlos A. Zarate,Gustavo Vázquez,Colleen Loo
标识
DOI:10.1016/j.eclinm.2023.102127
摘要
Intranasal esketamine has received regulatory approvals for the treatment of depression. Recently a large trial of repeated dose racemic ketamine also demonstrated efficacy in severe depression. However, uncertainties remain regarding comparative efficacy, dosage, and the time course of response.
科研通智能强力驱动
Strongly Powered by AbleSci AI